Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant IL-31 is a laboratory-engineered form of the cytokine interleukin-31, a member of the IL-6 family primarily secreted by activated Th2 lymphocytes. It signals through a heterodimeric receptor complex consisting of IL-31 receptor alpha (IL-31RA) and the oncostatin M receptor (OSMR). IL-31 is a potent inducer of pruritus and has been implicated in the pathogenesis of inflammatory skin diseases such as atopic dermatitis. In the context of respiratory research, recombinant IL-31 is utilized to investigate the role of the IL-31/IL-31RA axis in airway hyperresponsiveness and smooth muscle contraction. Recent studies suggest that while IL-31RA may contribute to asthma pathology, its effects on airway smooth muscle may be ligand-independent, as exogenous recombinant IL-31 does not necessarily enhance airway contraction in murine models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on interleukin-31.